KD Biopharma has different projects under assessment and is currently in the process of conducting Phase III of an orphan Drug named Alfa® indicated for the treatment of Familial Adenomatous Polyposis (FAP)
Alfa® has also shown to effectively help Ulcerative Colitis (UC) and Sporadic Polyps (SP) patients to keep the disease under control.
| Product candidate (Pathway) | Potencial indications | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 |
| Alfa® | FAP | |||||
| Alfa® | UC | |||||
| Alfa® | SP |